Research programme: high titre vaccinia immune globulin - OMRIX

Drug Profile

Research programme: high titre vaccinia immune globulin - OMRIX

Alternative Names: HT-VIG

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator OMRIX Biopharmaceuticals
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Smallpox

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Smallpox in USA (IV-injection, Injection)
  • 15 Aug 2006 Preclinical trials in Smallpox in USA (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top